复锐医疗科技（01696）股价今日盘中大跌5.64%，延续昨日超13%的跌幅，引发市场关注。截至盘中，该股报5.74港元，成交额1656.45万港元。
复锐医疗科技近日公布的2025年中期业绩显示，公司业绩出现明显下滑。期内收益为1.65亿美元，同比下降1.9%；母公司拥有人应占溢利为642.6万美元，同比大幅下降41.3%。公司表示，北美市场面临的挑战是业绩下滑的主要原因，包括高利率环境和消费疲软。此外，六月份由于地区紧张局势导致运输受限，也略微延迟了部分收益的确认。
尽管北美市场表现不佳，但复锐医疗科技在国际市场上仍取得了一定增长。公司称，若不计北美市场因素，其国际市场与去年同期相比实现了7.1%的增长。申万宏源分析认为，作为能量源医美器械的头部企业，复锐医疗科技依托直销网络强化了亚太地区的优势，注射填充业务有望成为第二增长曲线。虽然短期内北美市场压力较大，但长期发展逻辑未变，达希斐上市及联合治疗生态放量有望推动下半年业绩反弹。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.